Contribution of interleukin-6/gp 130 signaling in hepatocytes to the inflammatory response in mice infected with Streptococcus pyogenes.
暂无分享,去创建一个
C. Trautwein | T. Roskams | Werner Müller | O. Goldmann | E. Medina | L. Sander | U. Dierssen | C. Klein
[1] L. Lanier,et al. Cutting Edge: Inhibition of TLR and FcR Responses in Macrophages by Triggering Receptor Expressed on Myeloid Cells (TREM)-2 and DAP121 , 2006, The Journal of Immunology.
[2] H. Schild,et al. Protection from lethal septic peritonitis by neutralizing the biological function of interleukin 27 , 2006, The Journal of experimental medicine.
[3] B. Holzmann,et al. Organ-Specific Role of MyD88 for Gene Regulation during Polymicrobial Peritonitis , 2006, Infection and Immunity.
[4] C. Fielding,et al. Functional characterization of a soluble gp130 isoform and its therapeutic capacity in an experimental model of inflammatory arthritis. , 2006, Arthritis and rheumatism.
[5] R. Baron,et al. Pathobiology of sepsis: are we still asking the same questions? , 2006, American journal of respiratory cell and molecular biology.
[6] C. Hunter. New IL-12-family members: IL-23 and IL-27, cytokines with divergent functions , 2005, Nature Reviews Immunology.
[7] M. Neurath,et al. Involvement of IL-6 in the pathogenesis of inflammatory bowel disease and colon cancer , 2005, Clinical reviews in allergy & immunology.
[8] M. Kohanawa,et al. Endogenous Interleukin-6 Plays a Crucial Protective Role in Streptococcal Toxic Shock Syndrome via Suppression of Tumor Necrosis Factor Alpha Production , 2005, Infection and Immunity.
[9] M. Manns,et al. The IL-6-gp130-STAT3 pathway in hepatocytes triggers liver protection in T cell-mediated liver injury. , 2005, The Journal of clinical investigation.
[10] M. Béné,et al. A Soluble Form of the Triggering Receptor Expressed on Myeloid Cells-1 Modulates the Inflammatory Response in Murine Sepsis , 2004, The Journal of experimental medicine.
[11] P. Heinrich,et al. Characterization of the Signaling Capacities of the Novel gp130-like Cytokine Receptor* , 2004, Journal of Biological Chemistry.
[12] C. Coopersmith,et al. Antibiotics Improve Survival in Sepsis Independent of Injury Severity but do not Change Mortality in Mice with Markedly Elevated Interleukin 6 Levels , 2004, Shock.
[13] F. Bozza,et al. Antibiotic treatment in a murine model of sepsis: impact on cytokines and endotoxin release. , 2004, Shock.
[14] Duncan Young,et al. Epidemiology of severe sepsis occurring in the first 24 hrs in intensive care units in England, Wales, and Northern Ireland , 2003, Critical care medicine.
[15] M. Manns,et al. Lack of gp130 expression in hepatocytes promotes liver injury. , 2003, Gastroenterology.
[16] M. Manns,et al. ME3738 protects from concanavalin A‐induced liver failure via an IL‐6‐dependent mechanism , 2003, European journal of immunology.
[17] Werner Müller,et al. Interleukin 6/gp130‐dependent pathways are protective during chronic liver diseases , 2003, Hepatology.
[18] Hiroaki Ito. IL-6 and Crohn's disease. , 2003, Current drug targets. Inflammation and allergy.
[19] G. S. Chhatwal,et al. Immune mechanisms underlying host susceptibility to infection with group A streptococci. , 2003, The Journal of infectious diseases.
[20] R. Hotchkiss,et al. The pathophysiology and treatment of sepsis. , 2003, The New England journal of medicine.
[21] John D Lambris,et al. Protective Effects of IL-6 Blockade in Sepsis Are Linked to Reduced C5a Receptor Expression1 , 2003, The Journal of Immunology.
[22] J. Siddiqui,et al. Six at Six: Interleukin-6 Measured 6 H After the Initiation of Sepsis Predicts Mortality Over 3 Days , 2002, Shock.
[23] A. Lengeling,et al. Genetic control of susceptibility to group A streptococcal infection in mice. , 2001, The Journal of infectious diseases.
[24] M. Colonna,et al. TREM-1 amplifies inflammation and is a crucial mediator of septic shock , 2001, Nature.
[25] Lisa R Leon,et al. Role of IL-6 and TNF in thermoregulation and survival during sepsis in mice. , 1998, American journal of physiology. Regulatory, integrative and comparative physiology.
[26] D. Ilstrup,et al. Analysis of 281,797 consecutive blood cultures performed over an eight-year period: trends in microorganisms isolated and the value of anaerobic culture of blood. , 1997, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[27] R. Bone,et al. Gram-positive organisms and sepsis. , 1994, Archives of internal medicine.
[28] T. Calandra,et al. High circulating levels of interleukin-6 in patients with septic shock: evolution during sepsis, prognostic value, and interplay with other cytokines. The Swiss-Dutch J5 Immunoglobulin Study Group. , 1991, The American journal of medicine.
[29] P. Brandtzaeg,et al. The complex pattern of cytokines in serum from patients with meningococcal septic shock. Association between interleukin 6, interleukin 1, and fatal outcome , 1989, The Journal of experimental medicine.
[30] H. Volk,et al. Immunomodulatory therapies in sepsis , 2000, Intensive Care Medicine.
[31] A. Norrby-Teglund,et al. Correlation between serum TNF alpha and IL6 levels and severity of group A streptococcal infections. , 1995, Scandinavian journal of infectious diseases.